In this work, Based on differentially expressed genes (DEGs) detected from normal, pericancerous, cancerous liver samples by array technology, and the annotated gene sets from GSEA MSigDB, we managed to show some molecular transitional changes represented by different GO, pathway, regulatory gene sets.
The ability of these probes to detect copy gains in ASCUS and LSIL samples is significant in that molecular changes possibly representing underlying high-grade dysplasia can be discovered without the use of invasive procedures.
These changes represent common molecular features of drug abuse, which may underlie changes in synaptic function and plasticity that could have important ramifications for decision-making capabilities in drug abusers.
Epigenomic changes represent potential molecular attributes that define whether a carcinoma remains indolent or shifts toward an invasive phenotype.
Such alcohol-induced neurobiological changes represent possible molecular targets for pharmacotherapies of alcoholism, which help to facilitate abstinence or greatly reduce alcohol consumption by stabilizing neurobiological systems dysregulated by chronic alcohol use.
Molecular changes may, therefore, represent a better method of risk stratification in BO.
Since the time point for the molecular changes observed is five days after exposure, it is also possible that the changes represent secondary intermediate modes of change rather than specific early mechanistic interactions.
Moreover, HA molecular analysis showed, in four out of five SIVs, a unique significant AA change, represented by 2-AA-insertion at the HA receptor binding site (RBS).
In pharmaceutical modelling, cellular automata have been used as an established tool to represent molecular changes through discrete structural interactions.
These structural and molecular changes are believed to represent the basis for learning and memory, thereby underling both the developmental and activity-dependent remodelling of excitatory synapses.
